NovaBiotics Wins Life Science Business Leadership Award
NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company was awarded the Life Science Business Leadership Award at the Scottish Enterprise Life Sciences Annual Dinner on 6 February 2014 at the Edinburgh International Conference Centre.
The Life Science Business Leadership Award is presented to the business leader or management team who has significantly advanced their company in the previous year, with factors such as financing, partnerships, collaborations, achievement of milestones and growth being taken into consideration.
NovaBiotics’ CEO, Dr Deborah O’Neil, won the award for her leadership and vision which has been instrumental in the growth of NovaBiotics. After 11 years of work and 3 years of contract development, Deborah and her team secured an exclusive agreement with Taro Pharmaceuticals to license and co-develop the Company’s lead product Novexatin in August 2013, which is among the largest deals reached in the Scottish life science arena in recent years. NovaBiotics’ unique and ambitious strategy has also been recognised.
Dr O’Neil said: “I am proud of what NovaBiotics has achieved thus far and the Life Science Business Leadership Award reflects this. Our deal with Taro Pharmaceuticals is a huge success for the company and demonstrates industry confidence in our approach. By sticking to our business model and focusing on the results that our research was producing, we have created a solid foundation for our products and vision. Through all of this, we have been very fortunate to have been supported by organisations like the Scottish Enterprise, funding bodies, excellent, sector-specific mentors and a very talented team.”
The awards ceremony, hosted by Scottish Enterprise, recognises the success and achievements of Scotland’s internationally renowned life sciences sector in areas including innovation, investment, community engagement and collaboration. Scottish Enterprise identifies and exploits opportunities for Scotland's economic growth by supporting Scottish companies to compete, helping to build globally competitive sectors, attracting new investment and creating a world-class business environment.
Julia Brown, Director of Life and Chemical Sciences, Scottish Enterprise, said: “Congratulations to Dr O’Neil and to NovaBiotics. This is a fantastic achievement and the company’s continued success, including its international outlook, is very much testament to the innovation, drive and vision that Dr O’Neil demonstrates on a daily basis.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...